Psoriatic Arthritis | Unmet Need | US/EU | 2016
The tumor necrosis factor alpha (TNF-a) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. Meeting this challenge, several newer therapies have made advances in the PsA market in recent years with the availability of the first IL-12/23 inhibitor, the first IL-17 inhibitor, and the first oral PDE4 inhibitor. However, significant opportunity remains for novel mechanisms of action, new oral therapies, and treatments that can produce improved efficacy with decreased safety concerns.
